LTR Pharma has announced that it has increased its ownership in LevOmega Pty Ltd from 33% to approximately 43%. Through its wholly owned subsidiary, LTR Spectrum Pty Ltd, LTR Pharma has invested A$1.0 million to support the advancement of LevOmega’s research and development programs.
LevOmega was co-founded by LTR Pharma, Levur Pty Ltd and Green Blue Health Pty Ltd, and is focused on the development of sustainable, pharmaceutical-grade omega-3 products. This strategic investment further strengthens LevOmega’s capacity to advance technical validation, pilot production, and commercialisation of its proprietary omega-3 platform.
LTR Pharma Executive Chairman, Lee Rodne, said:
“We are delighted to deepen our commitment to LevOmega. This investment not only increases our equity stake to ~43% but also provides LevOmega with the resources to accelerate development of pharmaceutical-grade omega-3 products at a time when traditional fish oil supply chains are under increasing pressure from overfishing, pollution, and declining ocean yields.
“For LTR Pharma, this investment underscores our ability to identify and support scalable, first-in-class solutions that address global sustainability challenges while remaining highly complementary to our core intranasal pharmaceutical pipeline.”